All In Biotech

Drug Trial Radar · NCT04472728

Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients

Adaptive Design, Phase 2-3, Randomized, Double-blind, Multicenter Study, Evaluating Safety, Efficacy, PK-PD of BIO101 in Prevention of Respiratory Deterioration in Hospitalized Patients With COVID-19 Pneumonia (Severe)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

238

Actual

Start

Aug 26, 2020

Primary completion

Jun 6, 2022

Study completion Jun 6, 2022

Sponsor

Lead sponsor
BiophytisIndustry
Sponsor type
Industry
First posted
Jul 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia. Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide preliminary data on the activity, safety and tolerability of BIO101 in the target population. Part 2 is a phase 3 pivotal randomized study to provide further evidence of safety and efficacy of BIO101 after 28 days of double-blind dosing. BIO101 is the investigational new drug that activates the Mas receptor (MasR) through the protective arm of the Renin Angiotensin System (RAS).

Conditions

  • Covid-19
  • SARS-CoV2

Interventions

  • BIO101Drug

    BIO101 capsules

  • PlaceboDrug

    placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Negative EventsTime frame: Up to 28 days

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Abrazo Health

    Phoenix, Arizona

  • University of California, Irvine

    Irvine, California

  • Barnum Medical Research, Inc. 1029 Keyser Ave Suite H

    Natchitoches, Louisiana

  • Beaumont Health

    Royal Oak, Michigan

  • United Health Services Hospitals

    Johnson City, New York

  • WellSpan Health

    York, Pennsylvania

  • CHU Saint-Pierre

    Brussels, Belgium

  • AZ-Sint Maarten

    Mechelen, Belgium

  • CHU CLU Namur (Saint-Elisabeth) Place Louise Godin

    Namur, Belgium

  • Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar

    São Paulo, Brazil

  • Hospital Vera Cruz

    Belo Horizonte, Minas Gerais, Brazil

  • Santa Casa de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Municipal de Barueri Dr. Francisco Moran

    Barueri, São Paulo, Brazil

  • Hospital e Maternidade Celso Pierro - PUCCAMP

    Campinas, São Paulo, Brazil

  • Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Centre Hospitalier Argenteuil

    Argenteuil, France

  • Centre Hospitalier Universitaire Bordeaux

    Bordeaux, France

  • Centre Hospitalier Rene Dubos

    Cergy-Pontoise, France

  • Centre Hospitalier Départemental de Vendée

    La Roche-sur-Yon, France

  • Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris

    Paris, France

  • Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital

    Paris, Paris Cedex 13, France

  • FDI Clinical Research - San Juan City Hospital

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.